FDA Pazdur's Opdivo Love Affair And Other Adventures

This year's Biopharma Congress conference in Washington had something for everyone – debates on the current drug pricing atmosphere, discussions about what's missing in the House-passed 21st Century Cures Act that may be included in the Senate's version of the legislation and an update about the status of those pending FDA biosimilars guidances, which was essentially to confirm they're still pending.